| Sharm R Stanger, CRNA | |
|
111 W State St, Boise, ID 83702-0001 | |
| (208) 336-0895 | |
| (208) 338-1796 |
| Full Name | Sharm R Stanger |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 17 Years |
| Location | 111 W State St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992923718 | NPI | - | NPPES |
| P00617237 | Other | MN | MEDICARE, RAILROAD |
| 389105000 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R1664474 (Minnesota) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 256594 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic - Arizona | 7012829930 | 1395 |
News Archive
Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables.
Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.
› Verified 4 days ago
| Entity Name | Mayo Clinic Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables.
Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.
› Verified 4 days ago
| Entity Name | Anesthesia Partners & Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336530997 PECOS PAC ID: 9931429198 Enrollment ID: O20150529000706 |
News Archive
Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables.
Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.
› Verified 4 days ago
| Entity Name | Hospitalist Medicine Physicians Of Arizona - Nogales |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487251799 PECOS PAC ID: 9335554625 Enrollment ID: O20210218002429 |
News Archive
Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables.
Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sharm R Stanger, CRNA 111 W State St, Boise, ID 83702-6127 Ph: (208) 336-0895 | Sharm R Stanger, CRNA 111 W State St, Boise, ID 83702-0001 Ph: (208) 336-0895 |
News Archive
Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables.
Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.
› Verified 4 days ago
Mr. Douglas Neurath, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 111 W State St, Boise, ID 83702 Phone: 208-336-0895 | |
Jordan B Wolff, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 111 W State St, Boise, ID 83702 Phone: 208-336-0895 Fax: 208-338-1796 | |
Nathan S Call, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2222 | |
Ashton Mieritz, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2121 | |
Kenneth Clark Stratton Jr., CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2559 | |
Diana San Juan Shimko, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-6416 | |
David Hansen, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 338 E Bannock St, Boise, ID 83712 Phone: 208-336-0895 |